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Abstract: Prescriptions of psychotropic medications have become an important intervention for many
children and adolescents with mental disorders, and the rise of these prescriptions is debated intensively
both among experts and the public. This review reports some recent international findings on point
prevalence rates, cross-country comparisons, and time trends in psychotropic medication prescriptions for
children and adolescents. Besides the total prescription rates, figures for antidepressants, antipsychotics,
stimulants, and anxiolytics prescriptions are provided. The overall prescription rates of psychotropics in
general and the major medication subgroups prescribed to children and adolescents vary substantially
between countries with the US consumption being markedly higher than the use in European countries.
However, even among the latter there are marked variations in findings. Studies reporting on time
trends clearly indicate that there was a marked increase in the use of psychotropics for children and
adolescents in the recent past. However, only a single study adjusted prevalence rates for the increasing
number of children and adolescents assessed and treated in institutions providing mental health care.
Considering the increasing numbers of children and adolescents seen in psychiatric services, the increase
of psychotropic medications is less strong though still pronounced enough to stimulate further reflections
on the use of these interventions.
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Key points 
Psychotropic medication is an important component of intervention 
for mental disorders in children and adolescents.
There is a similar general trend in many countries of increasing 
prescription rates for psychotropic medication in children and 
adolescents.
Although insufficiently controlled in almost all pharmoco-epidemio-
logical studies, most of this increase is probably due to increasing 
number of help-seeking patients.
The prescription rates for all major psychotropic medications vary 
substantially for most countries reflecting both variations in study 
design and in prescription cultures.
In almost all countries, the prescription rates for stimulants rank high-
est followed by those for antidepressants and antipsychotics.
Introduction
Treatment with psychotropic medication has become a 
cornerstone of intervention for child and adolescent men-
tal disorders. Although the prevalence rates for medication 
vary considerably between countries, there is the impres-
sion both among professionals and the lay public that the 
prescription rates for these medications are increasing. 
A recent forum article has put forward the great concern 
today that children are being over-treated with medication, 
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especially in the US [1] and has resulted in various com-
mentaries from international experts including the Euro-
pean perspective [2, 3]. The present editorial review aims 
at describing some major trends in the use of psychotropic 
medications in children and adolescents as reflected in 
selected major studies published since 2000. No attempt 
was made to cover all available studies in terms of a sys-
tematic study of the entire literature which would go 
beyond the scope of the present review. Rather, the analyti-
cal scheme of the present contribution will look at point 
prevalence rates in various countries, cross-country com-
parisons, and time trends in the use of these medications in 
general and for the major groups of psychotropics, namely, 
antidepressants, antipsychotics, stimulants, and anxiolyt-
ics. Due to very rare reports on the use of mood stabilizers, 
hypnotics, and alpha-agonists, these medications will not 
be addressed in the present review.
General use of psychotropics in children 
and adolescents
There are a few studies from various countries reporting 
point prevalence rates in the recent past for various psy-
chotropics combined. For instance, all the hypnotic, anxio-
lytic, and antidepressant prescriptions in a total population 
of 120,908 adolescents aged 13–17 years in a southern 
France area during the year 2002 resulted in a maximum 
prevalence of 6.3 % for the 17-year-old girls [4]. In a 
nationwide population-based study covering the total popu-
lation of 0–17 year olds in Iceland, the overall prevalence 
of any psychotropic drug use was 4.87 % of children and 
adolescents in 2007 [5]. Recently reported data from the 
US National Comorbidity Survey–Adolescent Supplement 
(2002–2004), a nationally representative survey of 10,123 
adolescents aged 13–18 years, indicate that the 12-month 
prevalence was 7.0 % for the use of at least one psycho-
tropic medication in this age group. Many, albeit far from 
all adolescents, had mental disorders for which the specific 
medications are clinically indicated [6].
Several studies performed cross-country comparisons. 
Psychotropic prescriptions in children and adolescents 
were compared in the UK and three other European coun-
tries with the largest markets for these medications (France, 
Germany, and Spain), three South American countries 
with the largest markets for these medications (Argentina, 
Brazil, and Mexico), and North America (Canada and the 
USA). It was found that the number of psychotropic pre-
scriptions for children has risen between the years 2000 
and 2002 in all nine countries, and seven have shown a sig-
nificant increase. In this comparative analysis, the UK had 
the highest percentage increase (68 %) whereas the lowest 
was Germany (13 %) [7]. In another comparative study, 
the annual prevalence of any psychotropic medication in 
youth for the year 2000 was significantly greater in the US 
(6.7 %) than in the Netherlands (2.9 %) and in Germany 
(2.0 %) [8].
In addition, several studies have analyzed general time 
trends in the use of psychotropic medications in children 
and adolescents. Changes in the full spectrum of psycho-
tropic medication treatment for youths were analyzed from 
1987 to 1996 in a population-based analysis of commu-
nity treatment data on nearly 900,000 youths enrolled in 
two US health care systems. The total psychotropic medi-
cation prevalence for youths increased two to threefold 
and included most classes of medication. In this study, 
the rapid growth since 1991 of Alpha-agonists, neurolep-
tics, and mood stabilizer anticonvulsants was particularly 
notable. The 1996 prevalence of any psychotropic medi-
cation among youths younger than 20 years was remark-
ably similar (5.9–6.3 %) across all three sites. It was con-
cluded that youth psychotropic treatment utilization during 
the 1990s nearly reached adult utilization rates [9]. In the 
Netherlands, the year prevalence of antipsychotics, benzo-
diazepines, antidepressants, and stimulants increased from 
1.11 % in 1995 to 2.29 % in 2001 [10].
Prescriptions for children and adolescents over a 15-year 
period from 1996 to 2010 were analyzed based on the entire 
dataset of 105,908 patient years in the Danish prescription 
register covering stimulants, antidepressants, antipsychot-
ics, and anxiolytics. This is the only study that calculated 
both non-adjusted age-standardized prevalence rates and 
adjusted age-standardized prevalence rates considering the 
increase in patient numbers over time. There was a ninefold 
increase from a low of 1.34 per 1,000 person-years in 1996 
to a high of 12.35 per 1,000 person-years in 2010 in total 
dispensed psychotropic medication for children and adoles-
cents in Denmark which was only twofold after adjusting 
for increasing patient numbers [11].
Antidepressants
Whereas there are quite a number of recent time-trend 
reports on the changing use of antidepressants in children 
and adolescents, there are only a few studies restricting 
their focus on point-prevalence studies in various countries. 
In an Italian region, prescriptions of antidepressants in 
2001 yielded a prevalence of 2.78 subjects per 1,000 inhab-
itants during 12 months. The prevalence progressively rose 
with age in both sexes and a female/male difference was 
evident in adolescents [12]. The US National Comorbidity 
Survey––Adolescent Supplement (2002–2004)—reported 
that 3.9 % of adolescents aged 13–18 years had received 
antidepressants during a 12-month period. In this study, 
the antidepressants were the most commonly used 
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psychotropic medication [6]. In the Icelandic investigation, 
23.4 per 1,000 children and adolescents in 2007 received 
antidepressants so that antidepressants were the second 
most prevalent psychotropic medication group [5].
One study compared antidepressant prevalence data in 
youths across three western European countries (Denmark, 
Germany, and the Netherlands) with US regional data. The 
population-based analysis was based on administrative 
claims data for the year 2000 in 0 to 19-year-old enroll-
ees who were part of the insured populations from these 
four countries having a total of from 72,570 to 480,680 
members. Utilization of antidepressants in the US dataset 
(1.63 %) exceeded that of three Western European coun-
tries (prevalence ranged from 0.11 to 0.54 %) by at least 
threefold. In addition, there were major variations in the 
use of subclasses; tricyclic antidepressants (TCAs) pre-
dominated in Germany while selective serotonin reuptake 
inhibitors (SSRIs) predominated in the US, Denmark, and 
the Netherlands [13].
Several studies have analyzed time trends of anti-
depressant prescription data in various countries. Pre-
scriptions for children and adolescents were analyzed 
in the UK based on the General Practise Research Data-
base between 1992 and 2001. Among the prescriptions, 
55.7 % were for TCAs, 41.3 % for SSRIs, and 2.9 % 
for other antidepressants. The antidepressant prevalence 
increased 1.7-fold during the observation period with 
TCAs prevalence decreasing by 30 % from 3.6 to 2.5 per 
1,000 and SSRIs prevalence increasing 10 times from 0.5 
to 4.6 per 1,000. It was concluded that SSRIs had gained 
popularity for the treatment of depression compared with 
TCAs [14].
In the US, the Medical Expenditure Panel Survey 
(MEPS) database for the years 1997–2002 was analyzed. 
The MEPS is a yearly survey of a nationally representative 
sample of civilian, non institutionalized US Households. 
The percentage of users increased from 1.3 % in 1997 to 
1.8 % in 2002 with adolescent use (2.1 % in 1997 versus 
3.9 % in 2002) accounting for the increase whereas there 
was no change among children younger than 13 years. Also 
among adolescents, the use rate remained stable during the 
years from 2000 to 2002. The increase was caused by the 
use of SSRIs and other newer antidepressants, whereas the 
use of TCAs remained stable in adolescents and declined in 
prepubertal children. The use of antidepressant was similar 
among males and females [15]. Another recent US study 
compared the MEPS data from 1996 to 2005 and found that 
the rate of antidepressant treatment increased from 5.84 % 
in 1996 to 10.12 % in 2005 indicating a broad marked 
increase in antidepressant treatment [16].
Similar to the observations in the US, the prevalence of 
antidepressants prescribed in Germany remained rather sta-
ble in more recent years, namely, at 3.43 per 1,000 in 2000 
and 3.74 per 1,000 in 2003. At this time, St John’s Wort 
products, which are approved for antidepressant use by the 
German drug agency, and TCAs accounted for more than 
80 % of antidepressant use and SSRIs represented only 
15 % of antidepressant use. However, there was a doubling 
of the use of SSRIs over the 4-year period. Adolescent girls 
aged 15–19 years had utilization rates ranging from 11.44 
to 13.82 per 1,000, and accounted for most antidepressant 
use. Overall, females were twice as likely as males to get 
an antidepressant [17].
Limitations in licensing of antidepressants in Germany 
excluding the use of SSRIs except fluoxetine since 2006 
have led to frequent off-label prescriptions. A recent study 
characterised antidepressant medication use with a particu-
lar focus on off-label prescribing in a retrospective cohort 
study including cross-sectional analyses based on claims 
data of 2,599,685 patients up to 17 years of age. The preva-
lence of antidepressant medication use was 1.84 per 1,000 
children in 2004, 1.57 per 1,000 in 2005, and 1.66 per 
1,000 in 2006. Of all prescribed antidepressants 42.09 % 
were TCAs, 34.58 % were SSRIs, 16.47 % were St John’s 
wort preparations, and 6.86 % were other antidepressants 
[18].
The recent Danish analysis of prescriptions of psycho-
tropics over the 15-year period from 1996 to 2010 based on 
the national prescription register observed an increase from 
0.28 to 2.67 per 1,000 person-years. However, after adjust-
ing for the increasing base rate of patients over time, the 
prevalence rates were only less than two times higher at the 
end compared to the beginning of the observation period. 
As in other studies, the increase in prescription rates for 
antidepressants was mainly due to increased use among the 
14–17 year olds [11].
Antipsychotics
Only a few studies reported point prevalence rates of the 
use of antipsychotic medication in the recent past. Based 
on a questionnaire sent out to all child and adolescent 
psychiatry departments and consultants with a 6 or 63 % 
response rates, respectively, 6.4 % of treated children and 
adolescents in Denmark on October, 1 in 2002 received 
antipsychotic medication. Two-thirds of the patients had 
been treated with a second-generation antipsychotic (SGA) 
[19]. In the above mentioned US National Comorbidity 
Survey—Adolescent Supplement (2002–2004)—during a 
1-year period 0.5 % of the adolescents had received antip-
sychotics [6].
Cross-country comparisons indicate that the use of antip-
sychotics was 1.5–2.2 times higher in the US than in the 
Netherlands and Germany in 2000 with the atypical antip-
sychotic subclass representing only 5 % of antipsychotic 
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use in Germany, but 48 % in the Netherlands and 66 % in 
the US [8].
Various studies reported time trends in the use of 
antipsychotic medication. In the UK, the overall preva-
lence of use of all antipsychotics increased from 0.39 
users per 1,000 in 1992 to 0.77 users per 1,000 in 2005 
[20]. Between 1993 and 2002, a sharp increase in antip-
sychotic treatment has also been observed among chil-
dren and adolescents in office-based medical practice in 
the US. From 2000 to 2002, 9.2 % of all mental health 
visits and 18.3 % of visits to psychiatrists included antip-
sychotic treatment and 92.3 % of visits with prescription 
of an antipsychotic included a SGA medication [21]. In 
Canada, antipsychotic drug recommendations for children 
with ADHD more than tripled between 2005 and 2009. 
The majority of antipsychotic drug recommendations 
were for SGA with attention-deficit/hyperactivity disorder 
(ADHD) being the most common therapeutic indication 
associated with an SGA recommendation [22]. In Texas, 
from 1996 to 2000, an additional 12.25 children and ado-
lescents per 1,000 enrolees (+160 %) were prescribed 
antipsychotics [23].
The above-mentioned recent analysis of Danish pre-
scriptions of antipsychotic medication over 15 years found 
an increase from 0.31 per 1,000 person-years in 1996 to 
2.05 per 1,000 person-years in 2010. Antipsychotics were 
significantly more frequently given to males and the 14–
17 year olds in each year [11].
Stimulants
There is evidence from various studies that among the vari-
ous psychotropic drugs the stimulants are most widely pre-
scribed in quite a number of countries including the US [9], 
the Netherlands [10], Iceland [5], and Denmark [11]. The 
2007 prevalence of attention-deficit hyperactivity disorder 
(ADHD) drug use including MPH as the most frequently 
prescribed drug among the total Nordic population varied 
from 1.23 per 1,000 inhabitants in Finland to 12.46 per 
1,000 in Iceland [24].
Further studies have documented the increasing pre-
scription rates for various countries. Data collected in two 
Medicaid programs and one health maintaining organiza-
tion for three one year periods in 1991, 1993, and 1995 
showed that there has been a 1.7- to 3.1-fold increase of 
prescriptions for preschoolers between 1991 and 1995 in 
the US [25]. Other data from the US show that an estimated 
35 per 1,000 of US children received stimulant medica-
tion in 2008, up from 24 per 1,000 in 1996 [26]. The most 
recent US report based on the 2011 National Survey of 
Children’s Health (NSCH) used parent reported data and 
found that the prevalence of medicated ADHD increased 
by 28 % from 2007 to 2011 [27]. In the Netherlands, the 
prevalence of stimulants increased from 1.5 per 1,000 in 
1995 to 7.4 per 1,000 in 1999 [28]. In France, the annual 
prevalence of methylphenidate per 1,000 was 1.1 in 2003, 
1.5 in 2004, and 1.8 in 2005 [29]. A German cross-sec-
tional study analyzed data from a random sample of some 
50,000–63,000 children and adolescents per calendar year 
who were insurants of a major insurance company in one 
federal state for the years 2000–2007. The study found that 
parallel to the increasing prevalence rates of ADHD the 
prescription rates for methlphenidate almost doubled from 
0.54 to 1.06 % for school-aged children [30].
A recent study from Sweden covered the total popula-
tion cohort of all individuals aged 6–45 years, alive during 
any calendar year from 2006 to 2009. In this cohort, other 
medications used for ADHD treatment, namely, atomox-
etine, amphetamine, or dexamphetamine were also consid-
ered in the analysis. The dispensing prevalence increased 
from 2.93 per 1,000 in 2006 to 6.98 per 1,000 in 2009. The 
increase was largest for adults and greater in women than 
in men [31].
In the above mentioned large Danish study based on 
a nationwide dataset covering all prescriptions over the 
15-year period between 1996 and 2010, the prevalence 
rates increased from 0.31 per 1,000 person-years in 1996 
to 7.29 per 1,000 person-years in 2010. After adjusting 
for the increasing overall number of patients, there was an 
eightfold increase of stimulant prescriptions over time with 
males receiving significantly more stimulants than females. 
Furthermore, the increase was significant for all age groups 
from 0 to 17 years [11].
Another recent Danish register study used data on all 
children born between 1990 and 2001 and found that from 
2003 to 2010 youth 6–13 years of age with autism spec-
trum disorders, ADHD, and other psychiatric disorders had 
4.7, 6.3 and 5.5-fold increases, respectively, in prescription 
rates of ADHD medications which besides methylpheni-
date also included the less frequent prescriptions for dexa-
mphetamine and atomoxetine [32].
Anxiolytics
Few recent studies have reported on point prevalence 
rates of medications using anxiolytics in children and 
adolescents. In the analysis of prescriptions, in 2002 for 
13–17 year olds in a southern France area, 20.1 per 1,000 
received anxiolytics [4]. The US National Comorbidity 
Survey—Adolescent Supplement (2002–2004)—found a 
prevalence rate of 0.8 % for anxiolytics in 13–18 year olds 
[6]. Although rarely used, anxiolytics were twice as com-
mon in Dutch (0.73 %) as in US (0.49 %) and German 
(0.41 %) youth [8].
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Two studies have reported rather stable time trend in 
the use of anxiolytics in children and adolescents. In Ice-
land, the prevalence ranged between 1.5 and 2.0 per 1,000 
in the 2003–2007 period [5], and in the nationwide Danish 
prescription register study, the prevalence rates were 0.44 
per 1,000 person-years in 1996 and 0.33 per 1,000 person-
years in 2010 indicating no significant change over time. 
No significant sex differences in the prescription rates were 
found but the 14–17 year olds had the highest rate [11].
Comment
The present review of the use of various psychotropics in 
children and adolescents centred around three major issues, 
namely, point prevalence rates in various countries, cross-
national comparisons of these rates, and time trends. A 
synthesis of the various study findings is impeded by pro-
nounced differences in study designs, databases, and ana-
lytical procedures. Furthermore, the variability in the use of 
medications reflects differences in diagnostic systems, the 
availability and use of clinical practice guidelines, drug reg-
ulation, health services organization, availability and allo-
cation of financial resources, and cultural attitudes toward 
childhood behavioral and emotional disturbances [33]. In 
addition to these limitations, the interpretation of the find-
ings of the few studies that performed direct cross-national 
comparisons of prevalence rates of prescribed psychotropic 
medication is hampered by lacking representativeness of 
the samples, rather short time periods of data collection in 
the majority of studies and varying composition of medica-
tions under study.
Even with these considerations in mind, one has to 
conclude that the findings on point prevalence rates indi-
cate marked international differences in the frequencies of 
prescription rates across countries both in the total amount 
of medications and for the various major psychotropic 
medication groups. Overall, the use of all psychotropics is 
many times greater in the US than in all other countries. 
However, also in Europe there is a marked gradient of pre-
scription rates with, for instance, Icelandic children and 
adolescents receiving higher prescription rates than those in 
other Scandinavian countries and with Danish children and 
adolescents having rather low prescription rates. A detailed 
comparison of the various point prevalence rates for the 
total medications and the various subgroups between the 
Danish and other international findings has been provided 
in a recent publication [11].
Central to the present review of recent reports on the 
epidemiology of psychotropic medication use in chil-
dren and adolescents is the finding that there are similar 
international trends of an increasing use of psychotropic 
medications in children and adolescents in the recent 
past. However, these trends differ markedly in magnitude 
reflecting a variety of factors of influence [33]. So far, 
sampling effects have not been considered sufficiently. 
The majority of studies are based on surveys or local sam-
ples from a circumscribed area with often unknown rep-
resentativeness. Accordingly, data in these studies came 
from audits drawn from medical practitioners in various 
international regions [7] or from other regional sources 
[12, 13], insurance companies [8, 13, 17], Medicaid in 
various US states [9, 13, 23], regional retail pharmacies in 
the Netherlands [10, 13, 28], the national health insurance 
fund for self-employed workers in France [29], or panels 
of a relatively small number of general practitioners in the 
UK [20].
Greater success in gaining representativeness may have 
been achieved in studies based on representative household 
panels like the representative annual survey of US House-
holds [15, 26]. A complete coverage of nationwide popu-
lations of prescriptions has only been received in the two 
recent Danish register studies based on either complete 
birth cohorts [32] or the complete population of children 
and adolescents receiving psychotropic medications [11].
Furthermore, interpretations of the magnitude of time 
trends are hampered by the fact that the majority of lon-
gitudinal studies were based on rarely more than two 
observation points in time. In addition, none of the study 
except the Danish register study on time trends [11] con-
trolled for changing total base-rates of number of patients 
over the years. Thus, these studies do not sufficiently take 
into account that much of the increase of prescriptions is 
due to an increasing awareness for mental problems in 
children and adolescents and higher referral rates to spe-
cialized institutions and professionals in the recent past let-
ting alone the question whether or not the true prevalence 
rates of mental disorders in this age range might even have 
increased per se.
Overall, in the recent past, the use of psychotropics in 
children and adolescents has increased remarkably, and 
the gap between adult and youth medication rates for 
mental disorders has narrowed substantially. As Rapoport 
concluded recently, the use of new treatments, such as 
stimulants and SSRIs, not only brought help to otherwise 
treatment-refractory patients but also has contributed to 
an over-acceptance of reductionistic biology [1]. Further-
more, market forces with the pharmaceutical companies 
as powerful actors in health care delivery systems also 
drove the process of over-prescribing with a large propor-
tion of prescriptions without proper clinical indication. 
However, as Taylor has pointed out recently, considering 
the large group of insufficiently diagnosed or undetected 
problems of mental health in children and adolescents, 
undertreatment is perhaps a bigger problem globally than 
overmedication [3].
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